To investigate changes in NGFR levels across a larger cohort of BRAF‐mutant melanoma patients, we analyzed two published RNA‐seq datasets involving matched samples from 21 tumors pre‐treatment and following emergence of resistance to different combinations of RAF/MEK inhibitors (Sun et al, 2014; Hugo et al, 2015). This evidence concerns the gene BRAF and melanoma.